September 2022 in “Journal of The American Academy of Dermatology” Dermatologists should monitor potassium levels in women taking spironolactone for acne, hair loss, and hirsutism.
Spironolactone is a promising alternative to antibiotics for treating acne in adult females.
20 citations
,
May 1990 in “Cleveland Clinic journal of medicine” Spironolactone may reduce excessive hair growth in women.
11 citations
,
October 2019 in “Cancers” Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.
8 citations
,
April 1988 in “Journal of endocrinological investigation” Topical spironolactone cream doesn't cause hormone-related side effects in the body.
6 citations
,
April 2013 in “Journal of Investigative Dermatology” Spironolactone might lower the chance of getting rosacea.
4 citations
,
December 2021 in “Journal of The American Academy of Dermatology” Doctors are prescribing spironolactone more often to treat acne and skin conditions in teenagers, and it seems safe and well-tolerated.
23 citations
,
July 1979 in “Canadian journal of biochemistry” Spironolactone reduces the number of androgen receptor sites in rat skin by blocking them with its metabolite.
October 2025 in “Saúde (Santa Maria)” Spironolactone is an effective and safe treatment for acne in adult women.
32 citations
,
August 1985 in “Clinical endocrinology” Spironolactone may help reduce hair growth and testosterone levels in some women with hirsutism.
July 2025 in “Dermatology Practical & Conceptual” Spironolactone is safe for treating hair loss in women without causing low blood pressure.
January 2023 in “Zenodo (CERN European Organization for Nuclear Research)” A new accurate and reliable method was developed to measure Spironolactone and Hydrochlorothiazide together in medicines.
183 citations
,
March 1982 in “JAMA” Spironolactone is a safe and effective treatment for reducing excessive hair growth in women.
1 citations
,
November 2020 in “Journal of The American Academy of Dermatology” GSK-36 downregulation with UTMD improves plaque stability in atherosclerosis treatment.
4 citations
,
November 1996 in “European journal of endocrinology” Spironolactone may help treat excessive hair growth in girls, but more research is needed.
21 citations
,
March 1982 in “JAMA” Spironolactone is effective and safe for treating excessive facial hair in women.
50 citations
,
August 1985 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Spironolactone reduces the enzyme activity that converts testosterone to DHT, helping treat excessive hair growth in women.
1 citations
,
April 1993 in “Problemy e̊ndokrinologii” Spironolactone effectively reduces symptoms of hyperandrogenism like hirsutism and acne.
1 citations
,
June 1987 in “British journal of dermatology/British journal of dermatology, Supplement” Most patients tolerated spironolactone for acne and hirsutism despite common side effects like menstrual changes and breast tenderness.
23 citations
,
July 1989 in “Postgraduate medical journal” Spironolactone did not make hair thinner in women with excess hair growth.
80 citations
,
January 1988 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Spironolactone can cause side effects like irregular bleeding, but lower doses may reduce these effects and still improve hirsutism.
1 citations
,
July 2024 in “Frontiers in Pharmacology” The woman delivered a healthy baby boy despite taking spironolactone during pregnancy.
17 citations
,
January 1986 in “Acta obstetricia et gynecologica Scandinavica” Spironolactone can reduce hair growth and testosterone in hirsutism, but is less effective than combined treatments.
6 citations
,
January 1984 in “PubMed” Spironolactone treatment reduced hair growth and androgen levels in hirsute women, but the overall effectiveness was just adequate.
54 citations
,
June 2015 in “Australasian Journal of Dermatology” Spironolactone is an effective and well-tolerated first-line treatment for hidradenitis suppurativa in women.
22 citations
,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
July 2020 in “Journal of the American Academy of Dermatology” Spironolactone does not increase the risk of breast cancer recurrence.
34 citations
,
January 1995 in “The Journal of Clinical Endocrinology and Metabolism”